 Treatment on this study consists of two drugs, Gleevec and Taxotere. Patients will be take four tablets of Gleevec daily throughout the study. After one week of Gleevec, patients will then begin receiving doses of Taxotere intravenously once a week for two weeks in a row followed by one week without Taxotere. 